Lantheus posted Q4 2025 worldwide revenue of USD 406.8 million, up 4.0%, and GAAP net income of USD 54.1 million. GAAP fully diluted EPS was USD 0.82, while adjusted fully diluted EPS was USD 1.67, up 4.7%. For FY 2025, worldwide revenue was USD 1.54 billion, GAAP fully diluted EPS was USD 3.41, and adjusted fully diluted EPS was USD 6.08. In Q4 2025, PYLARIFY sales were USD 240.2 million, down 9.7%, DEFINITY sales were USD 85.3 million, down 1.0%, and Neuraceq sales were USD 31.0 million. Lantheus said it repurchased USD 100 million of common stock in Q4 under a board-approved repurchase plan (approved in July 2025) and ended 2025 with USD 359.1 million in cash and cash equivalents, after acquisition payments of USD 276.4 million for Evergreen Theragnostics and USD 352.9 million for Life Molecular Imaging, and payment of approximately USD 300 million for share repurchases. The company said it is sharpening its strategic focus on innovative PET radiodiagnostics and pursuing value-maximizing alternatives for radiotherapeutic assets. Lantheus also said it completed the divestiture of its legacy SPECT business to SHINE Technologies (effective Jan. 1, 2026) and highlighted 2026 PDUFA dates for three radiodiagnostic assets: a new PSMA PET formulation (March 6), OCTEVY (March 29), and MK-6240 (Aug. 13), while PNT2003 remains subject to FDA approval and the resolution of Hatch-Waxman litigation. Lantheus issued FY 2026 guidance for revenue of USD 1.4 billion to USD 1.45 billion and adjusted fully diluted EPS of USD 5.00 to USD 5.25.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260700PRIMZONEFULLFEED9661748) on February 26, 2026, and is solely responsible for the information contained therein.